Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Frequently asked questions
What sector does Transgene SA (TNG) operate in?
Transgene SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Transgene SA (TNG) current stock price?
As of the latest data, Transgene SA stock price is €0.72, with a previous close of €0.72.
What is Transgene SA (TNG) current market capitalization?
Transgene SA market cap is approximately 200.34 million.
What is Transgene SA (TNG) Earnings Per Share (EPS)?
The trailing EPS is -€0.26, and the forward EPS is -€0.22.
Does Transgene SA (TNG) pay dividends?
No. Transgene SA does not pay a dividend.
What is Transgene SA (TNG) beta (volatility) score?
Transgene SA has a beta of 0.686, indicating lower volatility than the overall market.
